Top Markets
#1 TENDIES TENDIES +42.31%
#2 Cash Cat Cash Cat +24.22%
#3 Asteroid Shiba Asteroid Shiba +16.17%
#4 OSK OSK +15.36%
#5 龙虾 (Lobster) 龙虾 (Lobster) +10.93%
#6 Bluwhale Bluwhale +10.55%
#7 MarsCoin MarsCoin +8.17%
#8 Threshold Network Threshold Network +7.55%
#9 Pyth Network Pyth Network +7.25%
#10 Tornado Cash Tornado Cash +6.90%
Coin of the day
TENDIES TENDIES
Settings
Language
ENGLISH
Currency
USD
Theme
Oryzon Genomics S.A. Oryzon Genomics S.A.

Oryzon Genomics S.A.

ORY
Rank in Stocks #16843
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in... Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system), oncology, and hematology disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases; and ORY-4001, a selective HDAC-6 inhibitor for the treatment of neurological disorders, such as Charcot-Marie-Tooth disease (CMT), amyotrophic lateral sclerosis (ALS), and others. It also has collaborations in precision medicine with Columbia University in New York and the Institute of Medical and Molecular Genetics (INGEMM) at La Paz Hospital in Madrid psychometrically characterize patients with mutations in the SetD1A or Shank3 genes; and Cooperative Research and Development Agreement (CRADA) to sponsor several clinical trials. The company was incorporated in 2000 and is based in Cornellà de Llobregat, Spain.
Share Price
$3.31
Last synced: 2026-09-01
Market Cap
$271.03M
Change (1 day)
-0.36%
Change (1 year)
8.04%
Country
ES
Trade Oryzon Genomics S.A. (ORY)

Category

Healthcare
Operating Margin for Oryzon Genomics S.A. (ORY)
Operating Margin as of 2026 TTM: 0.00%
According to Oryzon Genomics S.A. latest financial reports and stock price the company's current Operating Margin (TTM) is 0.00%. At the end of 2026 the company had an Operating Margin of 0.00%.
Operating Margin history for Oryzon Genomics S.A. from 2026 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
Not enough data for the provided dates.
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
38.59% -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
28.81% -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
-149.01% -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
25.57% -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00% -
CH
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.